Home
IDYA
IDYA News

Latest IDEAYA Biosciences Inc. (IDYA) News on September 6, 2025

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

2 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls

The Fly

2 months ago

General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls

MT Newswires

2 months ago

Wells Fargo Initiates Coverage on IDEAYA Biosciences With Overweight Rating, $44 Price Target

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

PR Newswire

3 months ago

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

3 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

A Look At The Fair Value Of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Simply Wall St.

4 months ago

A Look At The Fair Value Of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

MT Newswires

4 months ago

IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors

MT Newswires

4 months ago

IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

PR Newswire

4 months ago

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

PR Newswire

4 months ago

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

Insider Monkey

4 months ago

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

PR Newswire

4 months ago

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

4 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

PR Newswire

5 months ago

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

MT Newswires

5 months ago

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

PR Newswire

5 months ago

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

PR Newswire

5 months ago

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

MT Newswires

5 months ago

IDEAYA's Eye Cancer Therapy Receives Breakthrough Therapy Designation From FDA

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

PR Newswire

5 months ago

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

5 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

PR Newswire

5 months ago

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform

Insider Monkey

6 months ago

IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform

MT Newswires

6 months ago

IDEAYA Biosciences, ATTMOS Collaborate to Advance Small Molecule Discovery for Undruggable Oncology Targets

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

PR Newswire

6 months ago

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

6 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)

Zacks

7 months ago

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)

MT Newswires

7 months ago

RBC Lowers Price Target on IDEAYA Biosciences to $57 From $61, Keeps Outperform, Speculative Risk

MT Newswires

7 months ago

IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

Zacks

7 months ago

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

MT Newswires

7 months ago

IDEAYA Biosciences Q4 Loss Widens, Revenue Rises

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PR Newswire

7 months ago

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

PR Newswire

7 months ago

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

Zacks

7 months ago

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

MT Newswires

7 months ago

IDEAYA Biosciences Appoints Joshua Bleharski as Finance Chief

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

PR Newswire

7 months ago

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

7 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

Insider Monkey

7 months ago

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

PR Newswire

7 months ago

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Simply Wall St.

7 months ago

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

PR Newswire

8 months ago

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

MT Newswires

8 months ago

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

PR Newswire

8 months ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

8 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

9 months ago

IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

PR Newswire

9 months ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

PR Newswire

9 months ago

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

Simply Wall St.

9 months ago

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

PR Newswire

9 months ago

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

PR Newswire

9 months ago

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

MT Newswires

9 months ago

IDEAYA Biosciences Nominates IDE892 as Development Candidate

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

PR Newswire

9 months ago

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

9 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

PR Newswire

9 months ago

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

9 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Insider Monkey

9 months ago

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

PR Newswire

10 months ago

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

PR Newswire

10 months ago

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

MT Newswires

10 months ago

IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

PR Newswire

10 months ago

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Business Wire

10 months ago

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

Zacks

10 months ago

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

MT Newswires

10 months ago

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, $27 Price Target

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

Simply Wall St.

10 months ago

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

PR Newswire

10 months ago

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

MT Newswires

10 months ago

IDEAYA Biosciences Q3 Loss Narrows

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

10 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Zacks

10 months ago

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

Zacks

10 months ago

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

MT Newswires

10 months ago

IDEAYA Biosciences Secures FDA Approval for IDE275's Investigational New Drug Application

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

PR Newswire

10 months ago

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

MT Newswires

10 months ago

IDEAYA Biosciences Reports 'Positive' Interim Phase 1 Data for Cancer Drug; Shares Rise Pre-Bell

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

PR Newswire

10 months ago

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

MT Newswires

10 months ago

UBS Initiates IDEAYA Biosciences With Buy Rating, $50 Price Target

MT Newswires

a year ago

Cantor Fitzgerald Initiates IDEAYA Biosciences at Overweight

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

PR Newswire

a year ago

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a year ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans

Clinical Trials Arena

a year ago

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans

MT Newswires

a year ago

Wedbush Trims Price Target on IDEAYA Biosciences to $52 From $54, Keeps Outperform Rating

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires

a year ago

Ideaya Biosciences Says Phase 2 Darovasertib Trial Showed 'Clinically Meaningful' Results

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

PR Newswire

a year ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

PR Newswire

a year ago

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

PR Newswire

a year ago

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a year ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PR Newswire

a year ago

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a year ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat

Simply Wall St.

a year ago

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Simply Wall St.

a year ago

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

MT Newswires

a year ago

Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $60, Maintains Outperform Rating

MT Newswires

a year ago

IDEAYA Biosciences Shares Gain After Company Reports Q2 Net Loss

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

PR Newswire

a year ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a year ago

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

MT Newswires

a year ago

IDEAYA Biosciences, Biocytogen Agree to Option, License Deal for Solid Tumors Treatment Program

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

PR Newswire

a year ago

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Business Wire

a year ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Business Wire

a year ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

PR Newswire

a year ago

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%

Zacks

a year ago

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%

MT Newswires

a year ago

Wedbush Cuts Price Target on IDEAYA Biosciences to $54 From $56, Maintains Outperform Rating

Share on Social Networks: